CryoLife to Host Webcast Discussing PROACT Xa Clinical Trial on December 7, 2020
ATLANTA, Nov. 19, 2020 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will host a webcast for investors and analysts to discuss progress with the Company's ongoing PROACT Xa trial on December 7, 2020 at 4:00 p.m. EST.
The webcast will include brief remarks by Pat Mackin, Chairman, President, and Chief Executive Officer of CryoLife Inc. followed by a presentation from Dr. John H. Alexander, Steering Committee Co-Chair of the PROACT Xa trial and Professor of Medicine at Duke University, and a Q&A session.
The PROACT Xa clinical trial is a prospective, multicenter, randomized, clinical trial to determine if patients with an On-X mechanical aortic valve can be maintained safely and effectively on apixaban (Eliquis®) rather than on warfarin. Patient enrollment in the trial began earlier this year and is expected to continue through 2021.
To listen to the live teleconference and participate in the Q&A session, please dial 201-689-8261 a few minutes prior to 4:00 p.m. ET. A replay of the teleconference will be available December 7 through December 14, 2020 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415. The conference number for the replay is 13713375.
The listen-only live webcast and replay can be accessed in the Investor Relations section of the CryoLife website at www.cryolife.com and selecting Webcasts & Presentations.
About the PROACT Xa Clinical Trial
Worldwide, there are approximately 340,000 surgical aortic valves replaced annually placing the worldwide aortic surgical valve market at approximately $1.2 billion.
ELIQUIS is a registered trademark of Bristol-Myers Squibb Company. Neither CryoLife nor the PROACT Xa Trial are affiliated with, sponsored, or endorsed by the Bristol-Myers Squibb Company.
The PROACT Xa rationale and study design manuscript was published by Jawitz et al. in the American Heart Journal (September 2020).
View original content to download multimedia:http://www.prnewswire.com/news-releases/cryolife-to-host-webcast-discussing-proact-xa-clinical-trial-on-december-7-2020-301176974.html
SOURCE CryoLife, Inc.
Company Codes: NYSE:CRY